Skip to main content
hello world

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates

PR Newswire - Thu May 11, 2023

Enrollment completed in first cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429

Read more at prnewswire.com